Citation Impact
Citing Papers
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
2011 Standout
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy in Advanced Non–Small-Cell Lung Cancer
2007
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 Standout
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
2010 Standout
A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer
2014
First-line chemotherapy for NSCLC: an overview of relevant trials
2002
EGFR Antagonists in Cancer Treatment
2008 Standout
Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: A phase II trial
2001
Idiopathic pulmonary fibrosis
2017 Standout
Establishing the Diagnosis of Lung Cancer
2013 Standout
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Histologic Considerations for Individualized Systemic Therapy Approaches for the Management of Non-small Cell Lung Cancer
2009
The role of liposomes in clinical nanomedicine development. What now? Now what?
2019 Standout
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Autoinflammatory Disease Reloaded: A Clinical Perspective
2010 Standout
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
2014 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)
2009 Standout
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
The treatment of advanced non-small cell lung cancer
2005
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature
2012
Lung Cancer
2008 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: A systematic review of randomized controlled trials
2007
Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials
2006
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
2011 Standout
Nanocarriers for delivery of platinum anticancer drugs
2013
Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease
2014 Standout
Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens
2001
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
2006 Standout
Sensors of the innate immune system: their link to rheumatic diseases
2010 StandoutNobel
The impact of emphysema in pulmonary fibrosis
2013
Cellular processing of platinum anticancer drugs
2005 Standout
Cetuximab in advanced non-small cell lung cancer
2006
Caspase Functions in Cell Death and Disease
2013 Standout
Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial
2010
Idiopathic pulmonary fibrosis
2017 Standout
Systemic amyloidosis
2015 Standout
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
EMT: 2016
2016 Standout
Actual status of antiinterleukin-1 therapies in rheumatic diseases
2010
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
2012 Standout
The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?
2007 Standout
Epidemiology of Idiopathic Pulmonary Fibrosis in Northern Italy
2016
Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study
2007
Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review
2015
Functional Specialization of Interleukin-17 Family Members
2011 Standout
Role of gemcitabine in cancer therapy
2005
Microtubules as a target for anticancer drugs
2004 Standout
The Inflammasomes
2010 Standout
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial
2009
Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin
2016
Idiopathic pulmonary fibrosis
2011 Standout
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel
2004
Platinum drugs in the treatment of non-small-cell lung cancer
2002
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
2009
The status of platinum anticancer drugs in the clinic and in clinical trials
2010 Standout
Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel–cisplatin versus vinorelbine–cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study
2004
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Epidemiology of idiopathic pulmonary fibrosis
2013
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis
2010 Standout
Idiopathic Pulmonary Fibrosis in United States Automated Claims. Incidence, Prevalence, and Algorithm Validation
2015
Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach
2009
Clinical usefulness of liposomal formulations in cancer therapy: lessons from the experiences of doxorubicin
2018
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Chemotherapy for advanced non-small cell lung cancer in the elderly population
2015
Paclitaxel Plus Carboplatin Versus Gemcitabine Plus Paclitaxel in Advanced Non–Small-Cell Lung Cancer: A Phase III Randomized Trial
2002
Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis
2012
Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer
2007
Non-steroid agents for idiopathic pulmonary fibrosis
2010
Lipoplatin Treatment in Lung and Breast Cancer
2010
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects
2008 StandoutNobel
Silver Nanoparticles: Synthesis, Characterization, Properties, Applications, and Therapeutic Approaches
2016 Standout
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
2002
Advances in Copper Complexes as Anticancer Agents
2013 Standout
Idiopathic Pulmonary Fibrosis
2018 Standout
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Epidemiological studies in idiopathic pulmonary fibrosis: pitfalls in methodologies and data interpretation
2015
Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of the Published Literature
2005
Works of A. Rapti being referenced
Epidemiology of interstitial lung diseases in Greece
2009
Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis
2006
Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study
2008
Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial
2001
9088 Phase III study of Lipoplatin plus Gemcitabine versus Cisplatin plus Gemcitabine in advanced NSCLC; interim analysis
2009
A phase II study of docetaxel (D) and gemcitabine (G) as second-line treatment in patients (pts) with advanced non-small cell lung cancer (NSCLC)
1999